PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS

被引：0
|
作者：
Higuchi, Fumi [1 ]
Wakimoto, Hiroaki [2 ]
Cahill, Daniel [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DRES-16
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [21] MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
    A. Das
    F. C. Henderson
    M. Alshareef
    G. B. F. Porto
    I. Kanginakudru
    L. K. Infinger
    W. A. Vandergrift
    S. M. Lindhorst
    A. K. Varma
    S. J. Patel
    D. Cachia
    Clinical and Translational Oncology, 2021, 23 : 612 - 619
  • [22] MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells
    Das, A.
    Henderson, F. C., Jr.
    Alshareef, M.
    Porto, G. B. F.
    Kanginakudru, I.
    Infinger, L. K.
    Vandergrift, W. A., III
    Lindhorst, S. M.
    Varma, A. K.
    Patel, S. J.
    Cachia, D.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (03): : 612 - 619
  • [23] Drugs targeting the mitochondrial pore act as citotoxic and cytostatic agents in temozolomide-resistant glioma cells
    Annalisa Lena
    Mariarosa Rechichi
    Alessandra Salvetti
    Barbara Bartoli
    Donatella Vecchio
    Vittoria Scarcelli
    Rosina Amoroso
    Lucia Benvenuti
    Rolando Gagliardi
    Vittorio Gremigni
    Leonardo Rossi
    Journal of Translational Medicine, 7
  • [24] Drugs targeting the mitochondrial pore act as citotoxic and cytostatic agents in temozolomide-resistant glioma cells
    Lena, Annalisa
    Rechichi, Mariarosa
    Salvetti, Alessandra
    Bartoli, Barbara
    Vecchio, Donatella
    Scarcelli, Vittoria
    Amoroso, Rosina
    Benvenuti, Lucia
    Gagliardi, Rolando
    Gremigni, Vittorio
    Rossi, Leonardo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
  • [25] Erratum: Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
    C R R Rocha
    C C M Garcia
    D B Vieira
    A Quinet
    L C de Andrade-Lima
    V Munford
    J E Belizário
    C F M Menck
    Cell Death & Disease, 2015, 6 : e1727 - e1727
  • [26] PLK1 inhibitor targets mismatch repair-deficient temozolomide-resistant tumors
    Higuchi, Fumi
    Cahill, Daniel P.
    Wakimoto, Hiroaki
    CANCER RESEARCH, 2017, 77
  • [27] Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
    File, Danielle M.
    Morgan, Katherine P.
    Khagi, Simon
    JCO PRECISION ONCOLOGY, 2020, 4 : 841 - 847
  • [28] Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition
    Wang, Jianjiao
    Zhou, Fenggang
    Li, Yang
    Li, Qingsong
    Wu, Zhichao
    Yu, Lili
    Yuan, Fei
    Liu, Jie
    Tian, Yu
    Cao, Yu
    Zhao, Yan
    Zheng, Yongri
    CELL CYCLE, 2017, 16 (24) : 2355 - 2365
  • [29] Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells
    Lee, Eun-Sang
    Ko, Kyung-Kon
    Joe, Young Ae
    Kang, Seok-Gu
    Hong, Yong-Kil
    ONCOLOGY LETTERS, 2011, 2 (01) : 115 - 121
  • [30] ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
    Yuan, Alice L.
    Ricks, Christian B.
    Bohm, Alexandra K.
    Lun, Xueqing
    Maxwell, Lori
    Safdar, Shahana
    Bukhari, Shazreh
    Gerber, Amanda
    Sayeed, Wajid
    Bering, Elizabeth A.
    Pedersen, Haley
    Chan, Jennifer A.
    Shen, Yaoqing
    Marra, Marco
    Kaplan, David R.
    Mason, Warren
    Goodman, Lindsey D.
    Ezhilarasan, Ravesanker
    Kaufmann, Ascher B.
    Cabral, Matthew
    Robbins, Steve M.
    Senger, Donna L.
    Cahill, Daniel P.
    Sulman, Erik P.
    Cairncross, J. Gregory
    Blough, Michael D.
    PLOS ONE, 2018, 13 (08):
12345